BIOMUNEX has established an in-house discovery process to identify innovative pairs of targets to create innovative BiXAb® antibodies. BIOMUNEX also assemble cutting-edge national and international academic teams and experts to discover new targets and new target pairs and advance the development of immuno-therapeutics for the treatment of solid tumor cancers, such as gastric, liver, lung, and colon cancers and hematological malignancies such as leukemia, lymphoma and multiple myeloma. BIOMUNEX has already established several collaborations, for instance with Dr. Amigorena and his team at Curie Institute in Paris, one of the most renowned research academic institutions in Europe. Collaboration with Curie Institute is focused on development of novel T cell redirection approach aiming to overcome limitations of current immuno-therapeutics therapeutics. Another collaborative project combines leading French academic groups from IRCM (Institut de Recherche en Cancérologie de Montpellier) and Tours University and is funded by the French Agence Nationale de la Recherche (ANR). BIOMUNEX has also established a collaboration with Professor M. Peipp at the Universitätsklinikum Schleswig-Holstein (University of Kiel, Germany) for testing BIOMUNEX’ lead candidates in solid tumor cancers and hematological malignancies. Other collaborative projects that are subsidized by national grants, combine leading French and European academic groups. BIOMUNEX continues to actively establish scientific collaborations in France, as well as elsewhere in Europe and the US, in order to leverage the full potential of its unique BiXAb® platform.